Issued on behalf of Oncolytics Biotech Inc. USA News Group News Commentary VANCOUVER, BC, Jan. 15, 2025 /PRNewswire/ -- As 2025 begins, the American Association for Cancer Research (AACR) recently published forecasts from experts showcasing transformative advances in cancer research, including cutting-edge AI technologies, novel targeted therapies, and innovative cancer vaccines. With over 50 oncology drug approvals in 2024, including the first tumor-infiltrating lymphocyte cell therapy, this year holds gre ...

New pancreatic cancer cohort moves forward with full enrollment of 30 patients in Stage 1 SAN DIEGO and CALGARY, AB, Jan. 15, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that Germany's medical regulatory body, the Paul-Ehrlich-Institute (PEI), has approved the continuation of patient enrollment into Cohort 5 of the GOBLET study. This cohort is evaluating pelareorep in combination with mo ...

USA News Group CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Dec. 26, 2024 /PRNewswire/ -- USA News Group News Commentary – Immunotherapy is transforming oncology by harnessing the immune system's power to fight cancer like never before. Notable advancements include a bioengineered therapeutic platform that boosts immune responses, providing targeted solutions for challenging cancer types. Researchers have also introduced an mRNA-based immunotherapy platform capable of selectively tar ...

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Dec. 23, 2024 /PRNewswire/ -- USA News Group News Commentary – Recent advancements in cancer treatment continue to underscore the transformative potential of innovative therapies to improve patient outcomes. A stage 4 breast cancer patient in the United States reportedly achieved complete remission within six weeks through a novel immunotherapy approach, as highlighted by the New York Post. Meanwhile, in Europe, a Scottish woman became the first rec ...

Promising BRACELET-1 results in HR+/HER2- metastatic breast cancer lay the foundation for potential registration-enabling study and accelerated approvalAdvancing gastrointestinal cancer pipeline underscores potential for additional registration-enabling studiesSAN DIEGO and CALGARY, AB, Dec. 23, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, is providing a recap of the major accomplishments from 2024 and a ...

Company Developments - Oncolytics Biotech Inc. announced the presentation of two data sets showcasing pelareorep's potential in difficult-to-treat gastrointestinal cancers at the 2025 ASCO Gastrointestinal Cancers Symposium [2][8] - Cardiff Oncology reported positive initial data from its CRDF-004 trial, showing an objective response rate of 64% in patients receiving onvansertib in combination with standard care, compared to 33% in the control group [15][19] - Checkpoint Therapeutics received FDA approval for UNLOXCYT, marking a significant milestone for the company and providing a differentiated treatment option for patients with advanced cutaneous squamous cell carcinoma [5][20] Industry Trends - The global Cancer Immunotherapy Market is projected to grow at a CAGR of 12.84%, reaching $258.22 billion by 2031, indicating rapid growth and critical importance in oncology [7] - The American Cancer Society highlighted a concerning rise in early-onset colorectal cancer cases, exacerbated by disruptions in cancer care due to the COVID-19 pandemic [13] Collaborations and Partnerships - Personalis and Tempus AI expanded their commercial relationship to bring ultra-sensitive MRD testing to market, with Tempus serving as the exclusive commercial diagnostic partner for Personalis' NeXT Personal® Dx [4][10][16]

Core Insights - Oncolytics Biotech Inc. announced the acceptance of two abstracts for presentation at the 2025 ASCO Gastrointestinal Cancers Symposium, highlighting the potential of pelareorep in treating difficult gastrointestinal cancers [1][2] Company Overview - Oncolytics Biotech Inc. is a clinical-stage biotechnology company focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that has shown promising results in various cancer studies [3][4] - Pelareorep works by inducing anti-cancer immune responses and converting "cold" tumors into "hot" tumors, enhancing the effectiveness of existing cancer treatments [3] Clinical Data Presentation - The first abstract, titled "GOBLET platform study," will present preliminary safety and tumor response results for relapsed anal carcinoma patients treated with pelareorep and atezolizumab, scheduled for January 25, 2025 [2] - The second abstract, titled "GOBLET study," will discuss safety run-in results for first-line metastatic pancreatic ductal adenocarcinoma patients treated with pelareorep combined with modified FOLFIRINOX and/or atezolizumab, scheduled for January 24, 2025 [2] Regulatory and Clinical Development - Oncolytics is advancing towards registrational studies in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track designation from the FDA [4]

Condensed Interim Consolidated Financial Statements (unaudited) Oncolytics Biotech Inc. For the three and nine months ended September 30, 2024 ® ONCOLYTICS BIOTECH INC. CONDENSED INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (unaudited) (in thousands of Canadian dollars, except share amounts) | --- | --- | --- | --- | --- | |-----------------------------------------------------------------------------------------------------------------------------------------------|-------|----------------------|-- ...

BRACELET-1 data showing impressive overall survival benefit in HR+/HER2- metastatic breast cancer affirms pelareorep + paclitaxel combination should be evaluated in a registrational studyUpcoming GOBLET milestones include updated efficacy data from anal cancer cohort and safety run-in data from the modified FOLFIRINOX pancreatic cancer cohortCash position of $19.6 million as of September 30, 2024Management hosting conference call and webcast today at 8:30 a.m. ETSAN DIEGO and CALGARY, AB, Nov. 12, 2024 /PRN ...

Company Overview - Oncolytics Biotech Inc. is a clinical-stage biotechnology company focused on developing pelareorep, an intravenously delivered immunotherapeutic agent [3] - Pelareorep has shown promising results in clinical studies for metastatic breast cancer and pancreatic cancer, inducing anti-cancer immune responses and converting "cold" tumors to "hot" tumors [3][4] Upcoming Events - Oncolytics will host a conference call and webcast on November 12, 2024, at 8:30 a.m. ET to discuss corporate updates and financial results for Q3 2024 [1][2] Clinical Development - The company is conducting and planning combination clinical trials with pelareorep in various solid and hematological malignancies, advancing towards registrational studies in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track designation from the FDA [4]